financetom
Business
financetom
/
Business
/
JPMorgan lifts interest income forecast after profit beat
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JPMorgan lifts interest income forecast after profit beat
Jul 15, 2025 3:59 AM

(Reuters) -JPMorgan Chase raised its net interest income forecast for 2025 after strong performance in its investment banking and trading divisions helped it surpass profit expectations for the second quarter.

The bank now expects $95.5 billion of NII, or the difference between what it earns on loans and pays out on deposits, compared with an earlier estimate of $94.5 billion.

"The U.S. economy remained resilient in the quarter. The finalization of tax reform and potential deregulation are positive for the economic outlook," CEO Jamie Dimon said in a statement.

However, he highlighted that significant risks persist, including from tariffs and trade uncertainty, worsening geopolitical conditions, high fiscal deficits and elevated asset prices.

Investors are closely scrutinizing banks' results and their executives' commentary this quarter to assess the impact of tariffs and the tax and spending bill Trump signed into law earlier this month.

Market activity surged as investors seized opportunities and hedged risks in response to shifting U.S. tariff policies. The turmoil propelled JPMorgan's trading revenue 15% higher to $8.9 billion, driven by gains in both fixed income and equities.

Investment banking fees rose 7% to $2.5 billion, underpinned by a rise in initial public offerings and mergers and acquisitions.

Overall profit was $14.99 billion, or $5.24 per share, for the three months ended June 30, compared with $18.15 billion, or $6.12 per share, a year earlier, the largest U.S. bank said on Tuesday.

The comparisons were skewed by a nearly $8 billion one-off gain the bank had recorded on a share exchange agreement with Visa last year.

Excluding one-off costs, JPMorgan earned $4.96 per share, compared with the $4.48 per share that analysts were expecting, according to estimates compiled by LSEG.

Shares were marginally up before the open.

(Reporting by Niket Nishant in Bengaluru, editing by Lananh Nguyen and Anil D'Silva)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
RTX's Raytheon Awards Contract to Sener for Missile Production Support
RTX's Raytheon Awards Contract to Sener for Missile Production Support
Apr 29, 2024
12:06 PM EDT, 04/29/2024 (MT Newswires) -- RTX (RTX) said Monday its Raytheon business awarded Spanish supplier, Sener, a contract to develop and manufacture the electro-mechanical control section of the Patriot GEM-T missile. RTX said Sener will help support the recently awarded GEM-T production contract by the NATO Support and Procurement Agency for up to 1,000 missiles for a coalition...
--Paramount Suitor Skydance Offers $3 Billion to Repay Debt, Buy Back Stock Ahead of Potential Buyout, The New York Times Says
--Paramount Suitor Skydance Offers $3 Billion to Repay Debt, Buy Back Stock Ahead of Potential Buyout, The New York Times Says
Apr 29, 2024
12:01 PM EDT, 04/29/2024 (MT Newswires) -- Price: 12.39, Change: +0.48, Percent Change: +4.02 ...
Update: Bedford Metals Gains 6.7% as it Signs Definitive Option Agreement for the Ubiquity Lake Uranium Project
Update: Bedford Metals Gains 6.7% as it Signs Definitive Option Agreement for the Ubiquity Lake Uranium Project
Apr 29, 2024
12:01 PM EDT, 04/29/2024 (MT Newswires) -- Bedford Metals ( URGYF ) shares were least seen up 6.7% after the company said on Monday it reached a definitive option agreement for the Ubiquity Lake uranium project in Saskatchewan's Athabasca Basin. In early March, the company announced its intention to acquire the project. The Ubiquity Lake uranium project represents a significant...
Annovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 Study
Annovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 Study
Apr 29, 2024
12:12 PM EDT, 04/29/2024 (MT Newswires) -- Annovis Bio ( ANVS ) shares tumbled 58% in recent Monday trading after the company's phase 2/3 study of buntanetap to treat mild to moderate Alzheimer's disease missed an efficacy endpoint due to the limited number of patients and short trial duration. Annovis said it plans to conduct a pivotal disease-modifying phase 3...
Copyright 2023-2026 - www.financetom.com All Rights Reserved